The stock market has experienced a slowdown this year due to various macroeconomic and geopolitical headwinds. The major stock indexes are about to end the year with losses. However, healthcare major Gilead Sciences, Inc. (GILD) has delivered positive returns this year. GILD has gained 19.5% in price year-to-date and 20% over the past year to close the last trading session at $86.42.
GILD gained popularity during the pandemic by developing the first antiviral drug approved to treat COVID-19. GILD’s revenue and EPS in the last quarter were higher than analyst estimates. Its EPS came 32.9% higher than the consensus estimate, while its revenue beat analyst estimates by 14.8%.
